A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.08.066 ◽

2021 ◽

Author(s):

Nina Magnolo ◽

Külli Kingo ◽

Vivian Laquer ◽

John Browning ◽

Adam Reich ◽

...

Keyword(s):

Multicenter Study ◽

Plaque Psoriasis ◽

Pediatric Patients ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Severe Plaque Psoriasis

Download Full-text

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial

British Journal of Dermatology ◽

10.1111/bjd.19341 ◽

2020 ◽

Cited By ~ 4

Author(s):

R.B. Warren ◽

A. Blauvelt ◽

Y. Poulin ◽

S. Beeck ◽

M. Kelly ◽

...

Keyword(s):

Clinical Trial ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Severe Plaque Psoriasis

Download Full-text

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

British Journal of Dermatology ◽

10.1111/bjd.20595 ◽

2021 ◽

Author(s):

K.A. Papp ◽

M.G. Lebwohl ◽

L. Puig ◽

M. Ohtsuki ◽

S. Beissert ◽

...

Keyword(s):

Plaque Psoriasis ◽

Interim Analysis ◽

Efficacy And Safety ◽

Open Label ◽

Severe Plaque Psoriasis ◽

Term Efficacy ◽

Open Label Extension ◽

Extension Trial

Download Full-text

Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study

Advances in Therapy ◽

10.1007/s12325-021-01899-0 ◽

2021 ◽

Author(s):

Lin Cai ◽

Linfeng Li ◽

Hao Cheng ◽

Yangfeng Ding ◽

Zhenshu Biao ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Severe Plaque Psoriasis ◽

Phase Iii Study

Download Full-text

Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies

Drugs & Aging ◽

10.1007/s40266-018-0520-z ◽

2018 ◽

Vol 35 (2) ◽

pp. 135-144 ◽

Cited By ~ 23

Author(s):

Andreas Körber ◽

Charis Papavassilis ◽

Vaishali Bhosekar ◽

Maximilian Reinhardt

Keyword(s):

Plaque Psoriasis ◽

Pooled Analysis ◽

Phase Iii ◽

Elderly Subjects ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phase Iii Studies

Download Full-text

Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

American Journal of Clinical Dermatology ◽

10.1007/s40257-018-0353-x ◽

2018 ◽

Vol 19 (3) ◽

pp. 457-457 ◽

Cited By ~ 1

Author(s):

Andrew Blauvelt ◽

Kim A. Papp ◽

Christopher E. M. Griffiths ◽

Luis Puig ◽

Jamie Weisman ◽

...

Keyword(s):

Clinical Trials ◽

Plaque Psoriasis ◽

Randomized Clinical Trials ◽

Phase Iii ◽

Efficacy And Safety ◽

Two Phase ◽

Severe Plaque Psoriasis

Download Full-text

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2016.01.013 ◽

2016 ◽

Vol 74 (5) ◽

pp. 841-850 ◽

Cited By ~ 78

Author(s):

Kim A. Papp ◽

James G. Krueger ◽

Steven R. Feldman ◽

Richard G. Langley ◽

Diamant Thaci ◽

...

Keyword(s):

Plaque Psoriasis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Phase Iii ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Open Label ◽

Janus Kinase Inhibitor ◽

Phase Iii Studies

Download Full-text

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

British Journal of Dermatology ◽

10.1111/bjd.14164 ◽

2015 ◽

Vol 173 (6) ◽

pp. 1387-1399 ◽

Cited By ~ 201

Author(s):

C. Paul ◽

J. Cather ◽

M. Gooderham ◽

Y. Poulin ◽

U. Mrowietz ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Plaque Psoriasis ◽

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Phosphodiesterase 4 Inhibitor

Download Full-text

Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.08.019 ◽

2020 ◽

Vol 82 (2) ◽

pp. 389-397 ◽

Cited By ~ 7

Author(s):

Amy S. Paller ◽

Ying Hong ◽

Emily M. Becker ◽

Raul de Lucas ◽

Maria Paris ◽

...

Keyword(s):

Plaque Psoriasis ◽

Pediatric Patients ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Severe Plaque Psoriasis

Download Full-text

26860 Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate-to-severe plaque psoriasis: 52-week results from a randomized trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.493 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB119

Author(s):

Nina Magnolo ◽

Külli Kingo ◽

Vivian Laquer ◽

John Browning ◽

Adam Reich ◽

...

Keyword(s):

Randomized Trial ◽

Plaque Psoriasis ◽

Pediatric Patients ◽

Efficacy And Safety ◽

High Efficacy ◽

Severe Plaque Psoriasis

Download Full-text

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)

The Journal of Dermatology ◽

10.1111/1346-8138.13622 ◽

2016 ◽

Vol 44 (4) ◽

pp. 355-362 ◽

Cited By ~ 67

Author(s):

Hidehisa Saeki ◽

Hidemi Nakagawa ◽

Ko Nakajo ◽

Taeko Ishii ◽

Yoji Morisaki ◽

...

Keyword(s):

Plaque Psoriasis ◽

Japanese Patients ◽

Pustular Psoriasis ◽

Efficacy And Safety ◽

Open Label ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Generalized Pustular Psoriasis ◽

Open Label Phase ◽

Erythrodermic Psoriasis

Download Full-text